Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant
Sponsors
Vastra Gotalandsregionen, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Centre Oscar Lambret, Azienda Unita Sanitaria Locale Toscana Nord Ovest, Institut Gustave Roussy
Conditions
Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VINRecipients of allogeneic stem cell transplantationVulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)anal AIN) at the time of treatment.cervical CINcervical cancergiving a commercially available vaccine to women with HIV under treatmenthigh-grade cervical intraepithelial lesions
Phase 2
Vaccination against human papillomavirus (HPV) after allogeneic stem cell transplantation, a randomized study between early and late vaccination.
RecruitingCTIS2022-502912-35-00
Start: 2025-03-12Target: 100Updated: 2024-07-19
HPV2-2303 - Phase 2 clinical trial evaluating secondary HPV vaccination after treatment of high-grade cervical lesions
RecruitingCTIS2024-513081-19-00
Start: 2024-12-24Target: 85Updated: 2026-01-08
Phase 3
VulVaccin study: Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a Randomised Placebo Controlled Trial.
RecruitingCTIS2023-506792-94-00
Start: 2024-03-04Target: 498Updated: 2024-08-28
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of pre-surgical HPV9-valente vaccination in women treated with loop electrosurgical excision (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2+) up to cervical cancer initially invasive (FIGO IA1) - HOPE 9 STUDY
CompletedCTIS2024-513704-34-00
Start: 2021-10-01End: 2025-12-15Target: 1220Updated: 2024-06-24
Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women
The Papillon study
Not yet recruitingCTIS2024-520419-42-00
Target: 169Updated: 2025-01-30
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
Not yet recruitingCTIS2024-520140-42-00
Target: 984Updated: 2026-01-28